Market Overview:
Plasmid DNA is genetic material that is self-replicating in nature and found in bacteria. It is extensively used in molecular biology, biotechnology and gene therapy research. Plasmid DNA is widely used in immunotherapy, genetic engineering, regenerative medicines and gene therapies. Its ability to introduce new genetic materials into cells makes it indispensable for gene therapy research.
The Plasmid DNA manufacturing market is estimated to be valued at US$ 901.2 Bn or Mn in 2023 and is expected to exhibit a CAGR of 35% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends fueling the growth of the market is the rise in demand for plasmid DNA in mRNA vaccine and gene therapy research and development. Plasmid DNA plays a key role in the manufacturing of mRNA vaccines for diseases like Covid-19. With more pharmaceutical companies investing in developing mRNA based vaccines and gene therapies, the demand for high quality and GMP grade plasmid DNA is growing rapidly. Additionally, advancement in DNA delivery systems, reducing manufacturing costs and rising R&D investments are some other factors expected to drive the plasmid DNA manufacturing market over the forecast period.
Segment Analysis
The global Plasmid DNA Manufacturing market is segmented on the basis of vector type, application, end user and region. By vector type, the market is segmented into Bacterial Plasmid DNA and Mammalian Plasmid DNA, of which bacterial plasmid DNA dominates the market and accounts for over 60% share. This is because bacterial plasmid DNA is relatively inexpensive and easier to produce compared to mammalian versions. By application, the gene therapy segment dominates the market owing to the increasing research and development activities in gene therapy and rising government funding for the same.
Key Takeaways
The Global Plasmid DNA Manufacturing Market Size is expected to witness high growth, exhibiting a CAGR of 35% over the forecast period, due to increasing investments in pharmaceutical and biotechnology R&D.
Regional analysis:
North America accounts for the largest share in the global Plasmid DNA Manufacturing market, followed by Europe. This is due to presence of major pharmaceutical companies and large funding for gene therapy research in these regions. Asia Pacific is expected to witness the fastest growth during the forecast period supported by emerging economies like China and India increasing outsourcing of plasmid DNA manufacturing.
Key players:
Key players operating in the Plasmid DNA Manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing.
Get more insights on this topic:
https://www.rapidwebwire.com/plasmid-dna-manufacturing-market-size-analysis/
